Compared to traditional cell therapy such as CAR-T, in vivo Gene Therapy creates a simple drug model that is not encumbered by cell therapy manufacturing limitations. The ability to genetically modify (gene therapy) immune cells in the body will significantly lower cost, complexity and increase safety thus broadening access in oncology and expanding gene therapy into many more indications.  However, the ability to deliver genetic payloads specifically to immune cells with minimal off target impact (safety) and with the ability to redose (efficacy) remain significant challenges and limit the huge potential of gene therapy for the creation of therapeutic cells.  Lupagen has created a delivery device to address these challenges. At the bedside, peripheral blood immune cells are removed for a short time, incubated with the gene delivery vehicle and returned to the patient in a closed loop extracorporeal system similar to dialysis or plasmapheresis. Lupagen partners with biopharma companies to develop their in vivo gene therapy programs by supplying extracorporeal delivery systems for preclinical and clinical studies. In the US this is regulated as a combination product similar to an auto-syringe where the biopharma company maintains full control over their product. Lupagen simply supplies the devices and disposables required for clinical testing and into commercialization. The cost saving compared to cell therapy manufacturing is immense.